Journal article
The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities
U Dhagat, TR Hercus, SE Broughton, TL Nero, KS Cheung Tung Shing, EF Barry, CA Thomson, S Bryson, EF Pai, BJ McClure, JW Schrader, AF Lopez, MW Parker
Mabs | TAYLOR & FRANCIS INC | Published : 2018
Abstract
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor that can stimulate a variety of cells, but its overexpression leads to excessive production and activation of granulocytes and macrophages with many pathogenic effects. This cytokine is a therapeutic target in inflammatory diseases, and several anti-GM-CSF antibodies have advanced to Phase 2 clinical trials in patients with such diseases, e.g., rheumatoid arthritis. GM-CSF is also an essential factor in preventing pulmonary alveolar proteinosis (PAP), a disease associated with GM-CSF malfunction arising most typically through the presence of GM-CSF neutralizing auto-antibodies. Understanding the mechan..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council of Australia (NHMRC) [1117183]; National Health and Medical Research Council of Australia (NHMRC) [1071897].